Global Human African Trypanosomiasis (Sleeping Sickness) Market, By Type (Trypanosoma Brucei Gambiense (TbG), Trypanosoma Brucei Rhodesiense (TbR)), Symptoms (Stage 1: Fevers, Headaches, Itchiness, Joint Pains, Stage 2: Trouble Sleeping, Confusion, Poor Coordination), Treatment (Pentamidine, Suramin, Melarsoprol, Eflornithine and Nifurtimox when used in Combination with Eflornithine), Diagnostic Method (Blood Smear, Lumbar Puncture), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of the Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Global Human African Trypanosomiasis (Sleeping Sickness) Market
The global human African trypanosomiasis (sleeping sickness) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 7.0% in the above-mentioned research forecast period.
Human African trypanosomiasis (HAT), usually known as sleeping sickness is a vector-borne disease affecting humans in Sub-Saharan Africa. It is caused by parasitic protists of the species Trypanosoma brucei. It's two sub-species that can infect humans are gambiense and rhodesiense. Both types of the parasite are typically transmitted to humans via infected tsetse (genus Glossina), Tsetse is a large biting fly that dwells in affected regions. The parasites first develop in the blood, lymph and peripheral organs (stage 1) and further spread to the central nervous system (stage 2), where they cause severe neurological disorders. The diseases caused by these infections are generally fatal without treatment.
HAT is known to occur in rural areas of 36 countries in sub-Saharan Africa, where tsetse flies are endemic. T. b. gambiense is found in Central, West and some parts of Eastern Africa, whereas T. b. rhodesiense is found in southern and Eastern Africa. Of the estimated 10 000–30 000 cases in endemic areas of Africa, more than 95% of these cases are due to T. b. gambiense HAT. In the cases presented here, approximately 30% of cases were due to T. b. gambiense HAT and 70% were due to T. b. rhodesiense HAT.
The major problem in non-endemic regions is an initial misdiagnosis, mostly of T. b. gambiense HAT. The chronic nature, characterized by non-specific clinical signs and symptoms, and low parasitemia, may result in the disease remaining undiagnosed and unrecognized for years. Another problem was complicating the management of patients is the availability of drugs to treat HAT.
General recommendations to prevent tsetse-fly">tsetse fly bites include wearing light-colored clothing that fully covers the arms and legs, as well as the use of personal insecticides. The most effective means for preventing /trypanosomiasis">trypanosomiasis, both in travelers and in those living in endemic areas, is the control and reduction of vectors and reservoirs.
The governments of disease-endemic countries are committed to controlling the disease and several initiatives to coordinate efforts have begun. These include the Pan-African Tsetse and Trypanosomiasis Eradication Campaign and the Programme against African Trypanosomiasis.
The development of vaccines aimed to reduce T.b. transmission through immunization against insect parasite stages which express an invariant glycoprotein coat that is, blocking the parasitemia onset in the host, as the successful anti-tick vaccine. Several antigens have been already proposed as candidates for such experimental vaccination schemes and are being tested.
Only four drugs are approved to treat HAT. However, eflornithine and pentamidine are ineffective against sleeping sickness caused by T.b. rhodesiense. Treatment with melarsoprol, the only generally effective first-line drug, required lengthy parenteral administration and can result in up to 10% mortality. Additionally, the toxicity and the upsurge in the number of patients failing to respond to melarsoprol because of drug resistance reflect the need for the discovery of new chemotherapeutic agents against HAT. To this effect, the insufficiency of current therapies for the treatment and management of trypanosomiasis, combined with both a lack of trust in conventional medical treatment and an inability of the economy to absorb the cost of pharmaceuticals, have created a growing public interest in alternative natural drugs from botanicals.
This human African trypanosomiasis (sleeping sickness) market provides details of market share, new developments and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the human African trypanosomiasis (sleeping sickness) market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Human African Trypanosomiasis (Sleeping Sickness) Market Scope and Market Size
The global human African trypanosomiasis (sleeping sickness) market is segmented based on type, symptoms, treatment and diagnostic method. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with the valuable market overview and market insights to help them in making strategic decisions for the identification of core market applications.
- Based on type, the human African trypanosomiasis (sleeping sickness) market is segmented into trypanosoma brucei gambiense (TbG) and trypanosoma brucei rhodesiense (TbR).
- Based on symptoms, the human African trypanosomiasis (sleeping sickness) market is segmented into stage 1: fevers, headaches, itchiness, joint pains and stage 2: trouble sleeping, confusion and poor coordination.
- Based on treatment, the human African trypanosomiasis (sleeping sickness) market is segmented into pentamidine, suramin, melarsoprol, eflornithine and nifurtimox when used in combination with eflornithine.
- Based on diagnostic method, the human African trypanosomiasis (sleeping sickness) market is segmented into blood smear and lumbar puncture.
Global Human African Trypanosomiasis (Sleeping Sickness) Market Country Level Analysis
The human African trypanosomiasis (sleeping sickness) market is analyzed and market size insights and trends are provided by type, symptoms, treatment and diagnostic method as referenced above.
North America dominates the human African trypanosomiasis (sleeping sickness) market due to changing lifestyle and also due to rising healthcare expenditure as well as increasing availability of funds for research, huge patient population, well-developed healthcare sector coupled with increasing government support for research & development in the region.
The countries covered human African trypanosomiasis (sleeping sickness) market reports are the U.S., Canada, Mexico, Brazil, Argentina, Peru, the Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of the Middle East and Africa.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Human African Trypanosomiasis (Sleeping Sickness) Market Share Analysis
The human African trypanosomiasis (sleeping sickness) market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the human African trypanosomiasis (sleeping sickness) market.
The major players covered in the human African trypanosomiasis (sleeping sickness) market are Sara Healthcare Pvt. Ltd, Bayer Pharmaceutics Company, Scinopharm Taiwan.Ltd, Micro Orgo Chem, Rusan Pharma Ltd, Sanofi-Aventis groupe among others domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-